Ernest N. Morial Convention Centre December 10-13, 2022 Wednesday, December 14, 2022 American Society of Hematology Annual Meeting and Exposition is the world’s most comprehensive hematology event of the year. ASH is a professional society concerned with the causes and treatments of blood disorders. CCTG LY.17: A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma Type: Poster Session: 626 – Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I Presenter: Douglas Stewart Abstract: Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP (#1620) Authors: Stewart DA, Shepherd LE, Dudebout JJ, Larouche JF, Chua N, Baetz T, Crump M, Shafey M, Abdel-Samad N, Robinson S, Fleury I, Marcellus D, Skrabek P, Kelly J, Hay AE, Chen B, Kuruvilla J Link: https://ash.confex.com/ash/2022/webprogram/Paper163706.html Citation: Blood (2022) 140 (Supplement 1): 3734–3736. CCTG HD.7 / ECOG 2496: A Randomized Phase III Trial of ABVD Versus Stanford V with or without Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease Type: Oral Session: 624 – Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Advanced Stage and Relapsed Hodgkin Lymphoma Presenter: Angie May Rodday Abstract: Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium (#313) Authors: Rodday AM, Parsons SK, Friedberg JW, Gallamini A, Hawkes E, Hodgson DC, Johnson P, Link BK, Mou E, Savage KJ, Upshaw J, Zinzani PL, Maurer MJ, Evens AM Link: https://ash.confex.com/ash/2022/webprogram/Paper164720.html Citation: Blood (2022) 140 (Supplement 1): 760–762. CCTG LYC.1 / ECOG-ACRIN E1411: Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB -> R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV -> R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB -> LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV -> LR) Type: Oral Session: 623 – Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological I Presenter: Mitchell Smith Abstract: Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411 (#77) Authors: Smith MR, Jegede O, Martin P, Till BG, Parekh S, Yang DT, Kostakoglu L, Casulo C, Bartlett N, Caimi PF, Al Baghdadi T, Maddocks KJ, Romer MD, Inwards DJ, Lerner RE, Wagner LI, Little R, Friedberg JW, Leonard JP, Kahl BS Link: https://ash.confex.com/ash/2022/webprogram/Paper170381.html Citation: Blood (2022) 140 (Supplement 1): 186–188. Not Trial-Specific Type: Poster Session: 613 – Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II Presenter: Anna Blankstein Abstract: Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review (#2714) Authors: Blankstein AR, Sriranjan N, Choi N, Paulson K, Sanford D, Mozessohn L, Houston DS, Rimmer E, Lother S, Mendelson A, Garland A, Buckstein R, Hay AE, Zarychanski R, Houston BL Link: https://ash.confex.com/ash/2022/webprogram/Paper170961.html Citation: Blood (2022) 140 (Supplement 1): 11656–11657 CCTG ALC.7: Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH clinical trials Type: Poster Session: 616 – Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III Presenter: Richard Little Abstract: Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative (#4080) Authors: Little RF, Othus M, Assouline S, Ansher S, Atallah EL, Lindsley RC, Freidlin B, Gore SD, Harris L, Hourigan CS, Ivy SP, Jiwani S, Langan E, Luger SM, Michaelis LC, Odenike O, Patton D, Perales MA, Radich JP, Ramineni B, Salk JJ, Stiff P, Stock W, Stone RM, Uy GL, Williams PM, Wood BL, Worthington KH, Yee LM, Zeidan AM, Zhang J, Litzow MR, Erba HP. Link: https://ash.confex.com/ash/2022/webprogram/Paper169307.html Citation: Blood (2022) 140 (Supplement 1): 9057–9060. Not Trial-Specific Type: Poster Session: 621 – Lymphomas: Translational-Molecular and Genetic Poster III Presenter: Ryan Morin Abstract: Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL (#4172) Authors: Rushton CK, Rys RN, Chavez E, Hilton LK, Alcaide M, Dreval K, Cheung M, Cruz M, Coyle KM, Meissner B, Ben-Neriah S, Michaud NR, Daigle S, Davidson J, Wong J, Hay AE, Jain MD, Shepherd LE, Marra MA, Kuruvilla J, Crump M, Mann KK, Assouline S, Steidl C, Scott DW, Johnson NA, Morin RD Link: https://ash.confex.com/ash/2022/webprogram/Paper169623.html Citation: Blood (2022) 140 (Supplement 1): 9259–9260. CCTG ALC.4 / ECOG-ACRIN E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults. Type: Oral Session: Late-Breaking Abstracts Session Presenter: Mark Litzow Abstract: Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial (#LBA-1) Authors: Litzow MR, Sun Z, Paietta E, Mattison RJ, Lazarus HM, Rowe JM, Arber DA, Mullighan CG, Willman CL, Zhang Y, Wieduwilt M, Liedtke M, Bergeron J, Prat KW, Dinner S, Frey NV, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Little RF, Luger SM, Tallman MS Link: https://ash.confex.com/ash/2022/webprogram/Paper171751.html Citation: Blood (2022) 140 (Supplement 2): LBA-1. On-Line Abstract Publications Abstract: Supportive Care Strategies in Myelodysplastic Syndromes and Acute Myeloid Leukemia in Older Adults: A National Survey of Canadian Hematologists Authors: Blankstein AR, Choi N, Mozessohn L, Sanford D, Paulson K, Rimmer E, Houston DS, Lother S, Mendelson A, Garland A, Zarychanski R, Hay AE, Buckstein R, Houston BL Citation: Blood (2022) 140 (Supplement 1): 11656–11657. Abstract: Evaluation of Bleeding and Thrombocytopenia in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review Authors: Yang J, Choi, N, Paulson K, Sanford D, Mozessohn L, Houston DS, Rimmer E, Lother S, Mendelson A, Garland A, Buckstein R, Hay AE, Zarychanski R, Houston BL Citation: Blood (2022) 140 (Supplement 1): 12315–12316 Abstract: Evaluation of Infection in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review. Authors: Yang J, Choi, N, Mozessohn L, Sanford D, Paulson K, Houston DS, Rimmer E, Lother S, Mendelson A, Garland A, Buckstein R, Hay AE, Zarychanski R, Houston BL. Citation: Blood (2022) 140 (Supplement 1): 12317–12318 Abstract: Evaluation of Bleeding and Thrombocytopenia in Older Adults with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review and Meta-Analysis Authors: Sriranjan N, Blankstein AR, Choi N, Paulson K, Sanford D, Mozessohn L, Houston DS, Rimmer E, Lother S, Mendelson A, Garland A, Buckstein R, Hay AE, Zarychanski R, Houston BL Citation: Blood (2022) 140 (Supplement 1): 11632–11633.
